SC 003Alternative Names: SC-003
Latest Information Update: 29 Jul 2016
At a glance
- Originator Stemcentrx
- Class Drug conjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Ovarian cancer
Most Recent Events
- 01 Aug 2015 Phase-I clinical trials in Ovarian cancer (Second-line therapy or greater) in USA (IV)